Neutrophilic dermatoses and inflammatory bowel diseases

Giornale Italiano di Dermatologia e Venereologia

Volumn 148, Issue 2, 2013, Pages 185-196

  Marzano, A V ^a   Menicanti, C ^a   Crosti, C ^a   Trevisan, V ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Inflammatory bowel diseases; Pyoderma gangrenosum; Skin diseases; Sweet syndrome

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLOBETASOL; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DOXYCYCLINE; ETANERCEPT; IMMUNOGLOBULIN; INDOMETACIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; POTASSIUM IODIDE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANUS FISSURE; ANUS FISTULA; ASEPTIC ABSCESS SYNDROME; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG INDICATION; ENTERITIS; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; IMMUNE MEDIATED DERMATOSIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METASTATIC CROHN DISEASE; MONOTHERAPY; MOUTH CROHN DISEASE; PATHOGENESIS; PLASMAPHERESIS; PYODERMA GANGRENOSUM; PYOSTOMATITIS VEGETANS; REVIEW; SUBEPIDERMAL AUTOIMMUNE BLISTERING DISEASE; TREATMENT INDICATION; VASCULITIS;

EID: 84879005175     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 1009;361:2066-78.
2. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:597-605.
3. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22. (Pubitemid 32319146)
4. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A et al. Extra-intestinal manifestation of IBD in Veszprem county (of Hungary): Results of a 25-years follow-up study. Orv Hetil 2003;144:1965-75.
5. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Diaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: Differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005;125:297-300. (Pubitemid 41452251)
6. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006;12:212-7.
7. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 201;1:2702-7.
8. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011;106:110-9.
9. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol 2012;3:13.
10. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31. (Pubitemid 44323206)
11. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 2009;10:301-12.
12. Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a 'clinicotherapeutic' classification. J Dermatolog Treat 2011;22:254-60.
13. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012;13:191-211.
14. André M, Aumaître O. Aseptic abscesses syndrome. Rev Med Interne 2011;32:678-88.
15. Nesterovitch AB, Gyorfy Z, Hoffman MD, Moore EC, Elbuluk N, Tryniszewska B et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol 2011;178:1434-41.
16. Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 2011;7:469-78.
17. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784-90.
18. Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012;12:22-30.
19. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961-9. (Pubitemid 34449783)
20. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011;41:1203-17.
21. Binus AM, Qureshi AA, Li VW. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011;165:1244-50.
22. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012;132:2166-70.
23. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409. (Pubitemid 26083814)
24. Lyon CC, Smith AJ, Beck MH, Wong GA, Griffiths CE. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 2000;42:992-1002. (Pubitemid 30368667)
25. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004;43:790-800. (Pubitemid 39529936)
26. Callen JP. Pyoderma gangrenosum. Lancet 1996;351:581-5.
27. Marzano AV, Ishak RS, Lazzari R, Polloni I, Vettoretti S, Crosti C. Vulvar pyoderma gangrenosum with renal involvement. Eur J Dermatol 2012;22:537-9.
28. Marzano AV, Tourlaki A, Alessi E, Caputo R. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol 2008;33:156-9. (Pubitemid 351197208)
29. Marzano AV, Trevisan V, Galloni C, Alessi E. Fatal bullous pyoderma gangrenosum in a patient with Klinefelter's syndrome. Acta Derm Venereol 2008;88:158-9. (Pubitemid 351507189)
30. Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 1972;106:901-5.
31. Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol 2006;55:1066-71. (Pubitemid 44716487)
32. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008-17.
33. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis [PASH] - a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409-15.
34. Callen JP. Neutrophilic dermatoses. Dermatol Clin 2002;20:409-19. (Pubitemid 34840106)
35. Cantatore FP, Carrozzo M, Loperfido MC. Post biliopancreatic bypass arthritis: dermatitis syndrome. Clin Rheumatol 1991;10:449-51.
36. Jorizzo JL, Apisarnthanarax P, Subrt P, Hebert AA, Henry JC, Raimer SS et al. Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. Arch Intern Med 1983;143:457-61. (Pubitemid 13156434)
37. Patton T, Jukic D, Juhas E. Atypical histopathology in bowel-associated dermatosis-arthritis syndrome: A case report. Dermatol Online J 2009;15:3.
38. Brouard MC, Chavaz P, Borradori L. Acute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowel-associated dermatosis-arthritis syndrome and pustular pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2004;18:89-92. (Pubitemid 38159368)
39. Marzano AV, Ishak RS, Colombo A, Caroli F, Crosti C. Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis Syndrome following Bowel Bypass Surgery. Dermatology 2012;16,Epub ahead of print.
40. Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010;162:100-7.
41. Marzano AV, Trevisan V, Lazzari R, Crosti C. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat 2010;21:140-3.
42. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008;26:265-73. (Pubitemid 351978196)
43. Wasserteil V, Bruce S, Sessoms SL, Guntupalli KK. Pyoderma gangrenosum treated with hyperbaric oxygen therapy. Int J Dermatol 1992;31:594-6.
44. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-9.
45. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis 2009;15:803-6.
46. Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011;147:1203-5.
47. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201.
48. Cohen PR, Almeida L, Kurzrock R. Acute febrile neutrophilic dermatosis. Am Fam Physician 1989;39:199-204.
49. Cohen PR. Sweet's syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34.
50. Kumar G, Bernstein JM, Waibel JS, Baumann MA. (2004) Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol 2004;76:283-5. (Pubitemid 38828852)
51. Dereure O, Hillaire-Buys D, Guilhou JJ. Neutrophil-dependent cutaneous side-effects of leucocyte colony-stimulating factors: manifestations of a neutrophil recovery syndrome? Br J Dermatol 2004;150:1228-30. (Pubitemid 38932310)
52. Kemmett D, Hunter JA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol 1990;23:503-7. (Pubitemid 20281689)
53. Souissi A, Benmously R, Fenniche S, Zarrouk M, Marrek H, Debbiche A et al. Sweet's syndrome: a propos of 8 cases. Tunis Med 2007;85:49-53.
54. Carpentier O, Piette F, Delaporte E. Sweet's syndrome after BCG vaccination. Acta Derm Venereol 2002;82:221
55. Jovanović M, Poljacki M, Vujanović L, Duran V. Acute febrile neutrophilic dermatosis (Sweet's syndrome) after influenza vaccination. J Am Acad Dermatol 2005;52:367-9.
56. Vignon-Pennamen MD, Juillard C, Rybojad M, Wallach D, Daniel MT, Morel P et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol. 2006;142:1170-6. (Pubitemid 44414400)
57. Neoh CY, Tan AW, Ng SK. Sweet's syndrome: a spectrum of unusual clinical presentations and associations. Br J Dermatol 2007;156:480-5.
58. Sommer S, Wilkinson SM, Merchant WJ, Goulden V. Sweet's syndrome presenting as palmoplantar pustulosis. J Am Acad Dermatol 2000;42:332-4. (Pubitemid 30463683)
59. Sarkany RP, Burrows NP, Grant JW, Pye RJ, Norris PG. The pustular eruption of ulcerative colitis: a variant of Sweet's syndrome? Br J Dermatol 1998;138:365-6. (Pubitemid 28114156)
60. Bielsa S, Baradad M, Marti RM, Casanova JM. Sweet's syndrome with bullous lesions. Actas Dermosifiliogr 2005;96:315-6. (Pubitemid 40911033)
61. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol 1964;76:349-56.
62. Cullity J, Maguire B, Gebauer K. Sweet's panniculitis. Australas J Dermatol 1991;32:61-4.
63. Cohen PR. Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol 2005;52:927-8. (Pubitemid 40614675)
64. Kemmett D, Gawkrodger DJ, Wilson G, Hunter JA. Sweet's syndrome in Crohn's disease. BMJ 1988;297:1513-4. (Pubitemid 19007553)
65. Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993;11:149-57. (Pubitemid 23191681)
66. Ali M, Duerksen DR. Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can J Gastroenterol 2008;22:296-8. (Pubitemid 351676391)
67. André M, Aumaitre O, Marcheix JC, Piette JC. Aseptic systemic abscesses preceding diagnosis of Crohn's disease by three years. Dig Dis Sci 1995;40:525-7.
68. André M, Aumaître O, Grateau G, Chamaillard M, Costedoat-Chalumeau N, Cardoso MC et al. Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with Crohn disease in French patients. Dig Dis Sci 2010;55:1681-8.
69. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
70. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20. (Pubitemid 9242053)
71. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34. (Pubitemid 26244497)
72. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M et al.; DCCD study group. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82. (Pubitemid 43833122)
73. Yuksel I, Başar O, Ataseven H, Ertuǧrul I, Arhan M, Ibiş M et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546-50.
74. Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: a retrospective study. Indian J Dermatol Venereol Leprol 2008;74:607-10.
75. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580-5. (Pubitemid 41297914)
76. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42:97-114.
77. Requena L, Yus ES. Erythema nodosum. Dermatol Clin 2008;26:425-38.
78. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol 2011;7:235-41.
79. Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711-6. (Pubitemid 20185180)
80. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999;44:1-13. (Pubitemid 29053071)
81. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36. (Pubitemid 43137668)
82. Georgiou G, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron 2006;1:158-68.
83. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008;87:281-93.
84. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985;80:615-20. (Pubitemid 15040873)
85. Thornton JR, Teague RH, Low-Beer TS, Read AE. Pyoderma gangrenosum and ulcerative colitis. Gut 1980;21:247-8. (Pubitemid 10082937)
86. Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676-8.
87. Cariñanos I, Acosta MB, Domènech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:E153-4.
88. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012;107:794-5.
89. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg 2001;18:51-5. (Pubitemid 32217861)
90. Andrade P, Brites MM, Figueiredo A. Synchronous pyoderma gangrenosum and inflammatory bowel disease, healing after total proctocolectomy. An Bras Dermatol 2012;87:637-9.
91. Burrows NP. Sweet's syndrome in association with Crohn's disease. Clin Exp Dermatol 1995;20:279-80.
92. Ytting H, Vind I, Bang D, Munkholm P. Sweet's syndrome - an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005;72:195-200. (Pubitemid 41507280)
93. Benton EC, Rutherford D, Hunter JA. Sweet syndrome and pyoderma gangrenosum associated with ulcerative colitis. Acta Derm Venereol 1985;65:77-80. (Pubitemid 15153818)
94. Kang W, Hao C, Nie Q. Clinical challenges and Images in GI. Sweet syndrome in association with ulcerative colitis. Gastroenterology 2009;137:393.
95. Paoluzi OA, Crispino P, Amantea A, Pica R, Iacopini F, Consolazio A, et al. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet's syndrome. Case report and review of literature. Dig Liver Dis 2004;36:361-6. (Pubitemid 41115468)
96. Catalán-Serra I, Martín-Moraleda L, Navarro-López L, Gil-Borrás R, Pont-Sanjuán V, Ferrando-Marco J et al. Crohn's disease and Sweet's syndrome: an uncommon association. Rev Esp Enferm Dig 2010;102:331-7.
97. Travis S, Innes N, Davies MG, Daneshmend T, Hughes S. Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 1997;9:715-20. (Pubitemid 27315626)
98. Darvay A. Sweet's syndrome preceding inflammatory bowel disease. Clin Exp Dermatol 1996;21:175. (Pubitemid 26227965)
99. Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol 2005;12:145-9. (Pubitemid 43194357)
100. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 2005;68:376-9. (Pubitemid 41474747)